Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the review of Part IX of the Drug Tariff does not adversely impact investment by the medtech sector.

The Department is working closely with industry through the Drug Tariff Committee to finalise the detail of the update to the product categorisation and listing process of Part IX of the Drug Tariff. The Department remains committed to ensuring that the reforms represent a positive change for patients, the National Health Service, and the medical technology sector. For example, to support innovation and inward investment, a new two-year temporary listing mechanism will be introduced so that innovative products can be made available for patients more quickly.